Protara Therapeutics, Inc.
TARA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $109 | $21 | $30 | $76 |
| - Cash | $163 | $40 | $24 | $36 |
| + Debt | $4 | $5 | $6 | $7 |
| Enterprise Value | -$50 | -$13 | $12 | $47 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$49 | -$43 | -$65 | -$45 |
| % Margin | – | – | – | – |
| Net Income | -$45 | -$40 | -$66 | -$47 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.17 | -3.57 | -5.86 | -4.2 |
| % Growth | 39.2% | 39.1% | -39.5% | – |
| Operating Cash Flow | -$36 | -$38 | -$26 | -$35 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$36 | -$38 | -$27 | -$35 |